Ernexa Therapeutics Inc.
64.1M
$1.90M
-0.54
$-55.89
No price alerts set. Add an alert to get notified!
-0.54
3.15
$-55.89
-587.26%
0.00%
0.00%
Compare TSM with similar companies in the sector
| Company | Price | Change % | P/E | Market Cap | D/E |
|---|---|---|---|---|---|
|
ADAP
Adaptimmune Therapeutics plc
|
$0.05 | -3.00% | -0.01 | $12.53M | -0.69 |
|
AEMD
Aethlon Medical, Inc.
|
$2.38 | 0.85% | -0.17 | $1.81M | 0.06 |
|
AEON
AEON Biopharma, Inc.
|
$0.91 | -2.11% | -0.28 | $10.71M | -0.65 |
|
DWTX
Dogwood Therapeutics, Inc.
|
$1.65 | 14.58% | -0.70 | $3.15M | 0.00 |
|
LNAI
Lunai Bioworks Inc.
|
$0.31 | 0.42% | -0.06 | $5.58M | -0.22 |
|
MBRX
Moleculin Biotech, Inc.
|
$2.48 | -0.40% | -1.23 | $3.00M | 0.02 |
|
MPLT
MapLight Therapeutics, Inc.
|
$29.04 | 4.01% | -7.93 | $22.92M | 0.01 |
|
OSRH
OSR Holdings, Inc.
|
$0.58 | 12.72% | -0.12 | $14.99M | 0.06 |
|
PHGE
BiomX Inc.
|
$0.64 | -5.71% | -1.24 | $1.02M | -1.10 |
|
PMN
ProMIS Neurosciences, Inc.
|
$11.00 | -0.50% | -0.49 | $14.38M | 0.00 |
* Peer stocks are selected based on market capitalization and sector
$101.25
$3.18
$0.00
0.00%
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of solid tumors and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-102, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
